Skip to main content

Author: Hazel Norman

German Cannabis Legalization Bill Expected To Be In Cabinet By August

As Germany continues its high-profile quest to become the largest nation so far to pass a comprehensive, nationwide adult-use legalization bill, it is being reported that there is finally an estimated cabinet time-of-arrival for such a measure. A legalization measure is expected to be officially submitted to Germany’s cabinet by mid-August.

The announcement of an ETA for the measure comes after roughly two years of lawmakers in Germany haggling and negotiating over what the measure should include, with much of the discussion occurring behind closed doors.

The European Union’s mandatory inclusion in domestic German cannabis policy discussions increased the number of hurdles involved, and with it, increased the duration of the legalization process. However, the light at the end of the tunnel appears to be growing brighter.

At this point, it seems like a lifetime ago when the current governing coalition was elected in Germany back in the summer of 2021, mere weeks after a historic cannabis policy discussion was held at the International Cannabis Business Conference in Berlin.

At the 2021 conference in Berlin, German lawmakers discussed their intent to legalize cannabis in detail if/when the election results were favorable. As we now know, the election results did indeed prove to be favorable for legalization.

The next major milestone came in October 2022 when Germany’s Health Minister Karl Lauterbach presented his initial plan for German legalization, a plan that would later evolve after a series of meetings and discussions between the European Union and Minister Lauterbach.

The evolved plan would eventually be provided by Minister Lauterbach to German lawmakers earlier this year, and it has worked its way around closed political circles ever since. Although, the following provisions have surfaced:

  • All club properties where cannabis is cultivated and/or stored have to be tightly secured
  • Every club has to have a ‘trained addiction and prevention officer’
  • Must comply with residue limits for pesticides and fertilizers
  • Must track cannabis from seed
  • Annual reporting of crop amounts, including cannabinoid percentage (THC and CBD)
  • Club members only
  • 50 grams per month limit for over 21 years old
  • 30 grams per month limit for 18-20 years old
  • THC percentage cap for 18-20 years old (ten percent THC)
  • Neutral packaging
  • Labeled with specific harvest information

Much of what was leaked and reported on in Germany seems to surround noncommercial cannabis clubs, which will be strictly regulated and purely “cultivation associations.” According to domestic reporting, no cannabis can be consumed “within the clubs and within a radius of 250 meters.”

In addition to club provisions, items pertaining to individuals are also reportedly included in the current draft. Consumption is prohibited “within a radius of 250 meters from schools, daycare centers, playgrounds, youth facilities or sports facilities.” Also, consumption “should also not be permitted in pedestrian zones between 7 a.m. and 8 p.m.”

Consumers will be limited to one club membership at a time and permitted to cultivate up to 3 plants. Pharmacies are not allowed to cultivate or sell adult-use cannabis under the current plan, and medical cannabis “is to be removed from the scope of the Narcotics Act.”

In fact, medical cannabis reportedly has its own separate chapter in the latest draft law, which will hopefully provide a boost in safe access for patients, as well as help streamline cannabis research project approvals.

With all of that being said, until a final measure is officially adopted, nothing is ever a sure thing in Germany, and it is vital that advocates inside and outside of elected circles keep up the pressure to help ensure that laws and regulations are as sensible as possible and that whatever is adopted is seen as being a step in the right direction rather than a final destination.

A Missed Opportunity To Modernize Colombia’s Cannabis Policies

In Colombia, all constitutional amendments must undergo a two-year process, and since adult-use legalization requires a constitutional amendment, all such measures must undergo the multi-year process. An adult-use legalization measure sponsored by Rep. Juan Carlos Losada was successfully working its way through that process, however, the measure came up short this month.

Both chambers of Colombia’s Congress previously approved Rep. Losada’s measure last year, but due to the multi-year process, the bill still required a series of successful votes this year.

The Chamber of Deputies approved the legalization measure again last month, but despite a Senate committee approving the measure this year, the bill failed to receive the necessary 54 votes when receiving full floor consideration. Although, it is worth noting that the bill did receive a majority of votes (47-43).

Rep. Juan Carlos Losada made it clear in a tweet after the bill stalled that he will be back to introduce the measure again next month:

The tweet’s text auto-translates to, “We are not going to give up! We remain firm because we are sure that reaching 8th. debate is historic. With @PizarroMariaJo we will once again file the project to regulate the #CannabisDeUsoAdulto market on July 20.”

It’s unfortunate that the measure has to go back to the starting line and undergo, once again, a two-year process. Hopefully, this next time is a success, as there is clearly a significant level of support for Colombia to modernize its cannabis policies.

Jim Belushi Talks Cannabis Ahead Of Fireside Chat In Berlin

This year’s International Cannabis Business Conference event in Berlin will feature a one-on-one fireside chat with acclaimed entertainer Jim Belushi. Jim Belushi is a man of many talents – actor, singer, comedian, dancer, and now a legal cannabis farmer. We asked Belushi a series of cannabis questions ahead of his appearance in Berlin and below is what he had to say:

International Cannabis Business Conference: How does farming cannabis compare to your other pursuits?

Belushi: They both are on a mission to make people feel good, whether you’re making them laugh in a comedy or performing the Blues Brothers and filling their souls with music, or giving them cannabis to heal their anxieties, hopelessness, pain…. or just making them feel good and euphoric. The entertainment industry and the cannabis industry don’t hurt anybody. You can’t overdose if you laugh too much and you can’t overdose if you smoke too much pot. You may pass out if you eat too much of an edible, and I may have peed my pants from laughing too hard (especially at John Candy movies). But all in all, I’ve been at my business for 40 years and cannabis for 7 and they both have the same purpose — making people feel a little bit better. So I feel like I’m on track. They’re the same medicine.

International Cannabis Business Conference: Belushi’s Farm is located in Southern Oregon. What made you decide to choose that region?

Belushi: Southern Oregon chose me. My friend has a beautiful ranch down the Rogue River that I used to visit with my family twice a year. I went into the river naked one time and came out baptized, with a new spiritual release. I said to my friend, “Do you know of any other properties around here?” And that was it. I didn’t know Southern Oregon was the premiere spot to grow cannabis at the time… I was brought to Southern Oregon.

International Cannabis Business Conference: What types of products does your company make?

Belushi: Belushi’s Farm is home to a range of offerings including The Blues Brothers, Captain Jack’s Gulzar Afghanica (a rare strain from the Hindu Kush region that became known in the ’70s as “The Smell of SNL”), Good Ugly Weed, Belushi’s Farm premium brand. We’ve got a variety of products including flower, ice cream, hash and vape pens.

International Cannabis Business Conference: What markets are they available in? Do you have plans to expand to other continents?

Belushi: We’re currently available in Arizona, California, Colorado, Illinois, Maine, Massachusetts, Michigan, Mississippi, Nevada, New Mexico, New York, Oregon, Pennsylvania, and South Dakota. As for other continents, watch Season 3 of GROWING BELUSHI to see where we may take the adventure next!

International Cannabis Business Conference: What is your personal cannabis consumption regimen?

Belushi: I’m a microdoser. It’s medicine to me. I take 2.5-5mg of the Blues Brothers Bhang Chocolate to help me sleep. I’ll smoke a little Cherry Pie at the end of the day to help me with the transition into the evening. It’s medicine to me…“This medicine is so good, people take it FOR the side effects.”

International Cannabis Business Conference: What was your experience like making your hit show ‘Growing Belushi’ on the Discovery Channel? How did that cannabis-focused project compare to other projects you have worked on?

Belushi: This is a big question and deserves its own essay. But in short, all the other projects I’ve been involved with in show business have been scripted. Growing Belushi was all improvised, every scene, every moment. That takes a lot of concentration, a lot of wit, a lot of trust in your own ability, and a lot of overshooting to pull together an hour show each week. But that being said, it’s rewarding and joyous and fun when you’re able to create everything in the show. I love it.

International Cannabis Business Conference: What have you learned from visiting dispensaries in Oregon and beyond? 

Belushi: I visit a lot of dispensaries. In Oregon, I actually deliver to dispensaries and I do personal appearances and meet & greets. I have learned 85% of what I know about cannabis from these visits and experiences, which has changed this from a business to a journey to the pathway to healing. There are people, so many people, in need of medicine. From the veterans with PTSD, quadriplegics with spasms, people with shattered bones from car accidents, people with MS, dementia, sleeplessness, cancer on chemotherapy…the list goes on and on. In the dispensaries, I realized this was no longer just a business, it was necessary for the health of our community, for the people who suffer, the people who struggle, the people who are screaming inside the cavity of their bodies. I personally don’t use Ambien or Xanax for anxiety or even Advil. And I don’t really drink. Cannabis has replaced all these needs. I see a community growing larger in the pursuit of using cannabis as a substitute for medications and alcohol and opiates. I have been moved to tears many times.

International Cannabis Business Conference: What advice do you have for aspiring cannabis entrepreneurs?

Belushi: My advice to aspiring cannabis entrepreneurs is to stay out. The margins aren’t there yet. Between the fluctuation of the pricing of the pounds, the taxing, the banking, and the amount of initial capital, I would say don’t do it. Unless your passion overrides your pocketbook.

International Cannabis Business Conference: What is the biggest challenge facing the emerging cannabis industry today, in your opinion?

Belushi: The tens of thousands of nonviolent cannabis prisoners that are still in jail for the plant. That’s why I support Last Prisoner Project.

What do you have coming up that people should have on their radars?

Belushi: I have a lot of exciting stuff on the horizon. Follow me, my cannabis show ‘Growing Belushi,’ and my farm on social media and check out my website to keep up on all things Belushi. And, of course, join me in Berlin at the end of this month at the International Cannabis Business Conference where I will be doing a fireside chat, followed by a performance at the conference after-party. See you there!

International Cannabis Business Conference: What is the best way for folks to keep up on all of your cannabis industry pursuits?

Belushi: Through Instagram, Twitter, TikTok, and the website.

Medical Cannabis Safe Access To Expand In Israel

When it comes to medical cannabis research, Israel has long served as an international leader. After all, it is where International Cannabis Business Conference speaker alumni Raphael Mechoulam became the first person in history to isolate tetrahydrocannabinol (THC), in addition to numerous other cannabis research breakthroughs.

Unfortunately, general medical cannabis policy and safe access for domestic patients have never seemed to receive the same level of embrace and consideration in Israel for some reason, with many patients reporting gaps in being able to acquire their medicine.

Israel currently serves as the top importer of medical cannabis products, which doesn’t make a lot of sense since the country obviously knows how to harness the cannabis plant and maximize its potential. The only logical explanation is that the nation’s laws are holding the domestic medical cannabis sector back.

Thankfully, there appear to be meaningful changes on the way, with it being reported that Israeli medical cannabis patients will soon no longer be required to obtain a special license for medical cannabis, per a recently approved reform measure. Per YNetNews:

The Knesset’s Health Committee decided on Tuesday that access to medical cannabis will be significantly expanded, with many more patients qualifying – without the need to obtain a special license to use the drug.

The decision is part of a reform led by the Health Ministry in recent months. Within the reform’s framework, patients with a wide range of diseases and medical conditions will no longer be required to obtain a license in order to receive medical cannabis.

The reduced hurdles for obtaining medical cannabis are surely welcomed. With that being said, medical cannabis patients in Israel still are at the mercy of whatever supply they can access. As more patients presumably enter the medical cannabis sector as a result of the change, it will need to be met with boosts in domestic supply.

As is the case with any country, the only real way to ensure that every patient has safe access to medical cannabis is to legalize it for adult use, in addition to medical cannabis policies, and to afford every patient the right to cultivate their own medicine and/or join a noncommercial cannabis club.

French Town Wants To Launch Cannabis Pilot Program

By many measures, the concept of a cannabis commerce pilot program is a relatively new thing. While they are already in existence in Europe, it is only in recent years that they seem to have entered the mainstream policy reform conversation on the continent.

Switzerland has embraced the cannabis commerce pilot program more than any other nation so far. A cannabis commerce pilot program involves a jurisdiction being permitted to allow limited cannabis sales as part of ongoing government social science research.

In theory, by allowing limited cannabis sales, data can be collected, and the analysis of that local data can then help lawmakers and regulators be better suited to craft national cannabis policies. Cannabis commerce pilot programs have their limitations to be sure, however, for participants, it effectively results in legalized cannabis and the freedoms that go with it. Additionally, the concept is EU-approved and does not run afoul of EU agreements (unlike national legalization).

France has historically moved much slower on cannabis reform compared to some of its European counterparts, but if one small town has its way, it will launch its own cannabis commerce pilot program sooner rather than later. Per Newsweed:

The mayor of Bègles, a small town of 30,000 inhabitants close to Bordeaux, wants to make his city a territory for experimenting with the supervised legalization of cannabis.

Mayor Clément Rossignol Puech’s proposal to experiment with the production, sale and consumption of cannabis in Bègles has its origins in two recent reports: one from the Information Mission on the Uses of Cannabis, held to the National Assembly in 2021, and the other to the Economic, Social and Environmental Council (CESE) in 2023. These two reports came out in favor of a supervised legalization of cannabis.

While it is never easy to guarantee anything in the cannabis world, it does seem in increasing fashion that the cannabis commerce pilot program model is here to stay in Europe. Pilot programs are the focus of ‘phase 2’ of legalization in Germany according to the current plan, and pilot discussions in other countries appear to be heating up as well.

Pilot programs are clearly not as good as national legalization, such as what is found in Canada. However, when coupled with noncommercial clubs and home cultivation, such as what is being proposed in Germany, it can provide a significant amount of freedom to cannabis consumers. Hopefully other lawmakers join Mayor Clément Rossignol Puech’s push for pilot programs in France.

SOMAÍ Pharmaceuticals Signs Supply Contract With Cosma Poland

LISBON, Portugal (GLOBE NEWSWIRE) — SOMAÍ Pharmaceuticals Unipessoal LDA (“SOMAÍ”) has entered into a two-year supply agreement with a well-respected Polish distributor Cosma Cannabis. Cosma produces medical-grade cannabis products for importation and distribution across Poland. The contract represents 1,000,000 euros in sales for SOMAÍ’s 2024 goals to develop the fast-emerging medical cannabis markets of Poland.

“We are very proud that Cosma has chosen SOMAÍ Pharmaceuticals as their preferred manufacturer to penetrate the Polish market with our extract formulations,” said SOMAÍ Pharmaceuticals CEO and Chairman Michael Sassano. “Being one of the first manufacturers in a large market with positive regulatory reforms must have good partners like Cosma that can effectively educate and represent our current and future product offerings.”

By the terms of the agreement, SOMAÍ has agreed to supply medical cannabis products to Cosma for distribution in Poland under the trademark of Cosma. Additionally, Cosma will be granted Marketing Authorization to supply, market, and distribute the products within the designated territory. It has been stipulated in the agreement that Cosma will carry out the distribution of the products in compliance with the agreed-upon terms and conditions.

The medical cannabis products distributed under the Agreement consist of oil drops in various ratios of THC/CBD, including 25:1, 10:10, 2.5:25, and 20:1.

The Polish market for medical cannabis products has grown rapidly in recent years, with a number of patients seeking alternative treatments for conditions such as chronic pain, multiple sclerosis, and epilepsy. The demand for high-quality medical cannabis products in Poland is exceptionally high. SOMAÍ Pharmaceuticals’ products are especially needed in the Polish market due to their high quality and effectiveness in treating various medical conditions, such as chronic pain, multiple sclerosis, chemotherapy-induced nausea and vomiting, and epilepsy.

“Initiation cooperation with SOMAÍ has allowed us to offer innovative medicinal substances in the Polish market. We plan to develop products dedicated to Eastern Europe patients jointly. Due to the unique composition and the use of particular ingredients in these products, their absorption by the human body will be much greater than that of competitor’s products.” – said Lukasz Kreski, CHAIRMAN and Co-Founder of COSMA. “We also plan to begin joint clinical research and studies in pain management, inflammatory conditions, neurodegenerative diseases, and oncology.”

About SOMAÍ Pharmaceuticals Ltd.

SOMAÍ Pharmaceuticals is an international company focused on the extraction of the cannabis plant and manufacturing pharmaceutic formulations for the EU market. The company invests in the extraction, research, development, and distribution of EU GMP-pharmaceutical market-authorized cannabinoid products. For more information, please visit SOMAÍ’s website. You can read SOMAÍ’s and CEO Michael Sassano’s articles here.

Press Contacts:
Nataliia Garnina
Marketing Manager
+351 963 551 216
ng@somaipharma.eu

Commercial Contact:
Geroge Bellow
Chief Operational Officer
George@somaipharma.eu

ABOUT COSMA

Cosma Cannabis is a Polish cannabis company. Cosma offers natural and safe dietary supplements that are based solely on high-quality, natural herbal extracts and free of synthetic additives. By incorporating traditional herbal extracts such as chamomile, mint, and hops, Cosma’s products cater to the specific needs of patients. The key advantages of Cosma products include proven and consistent composition, easy dosing, and the absence of psychoactive tetrahydrocannabinol. For more information, please visit https://cosmacannabis.com/.

Commercial Contact:
Lukasz Kreski
Chairman/Co-Founder
lukasz.kreski@cosma.pl

Source: GlobeNewswire

What Is Next For The Cannabis Industry?

The emerging legal cannabis industry is continuing to undergo a dramatic evolution, particularly in Europe. The momentum for global reform is greater now than at any other time since the dawn of prohibition, and the biggest domino to date is teetering and getting closer to toppling with every passing day. That domino is, of course, Germany.

Cannabis advocates have fought for reform in Germany for many years, however, the legalization effort picked up considerable steam in mid-2021 when the results of the federal election that year yielded a governing coalition that quickly expressed its desire to modernize Europe’s cannabis policies.

Germany was already home to the largest legal medical cannabis industry in Europe at the time, and initially, it seemed that Germany would launch legal national adult-use cannabis sales in a quick fashion. Then, for over a year, German Health Minister Karl Lauterbach worked behind the scenes, with details of his legalization plan leaking every once in a while.

Eventually, Minister Lauterbach held a press conference in October 2022 to announce some of the provisions he would be seeking but made it abundantly clear that his next stop was the European Union to try to get its permission to proceed.

Unfortunately, the effort hit some turbulence once Germany’s Health Minister started negotiating with the European Union, with Minister Lauterbach providing an update in April 2023 in which he indicated that the European Union would allow parts of the previously outlined legalization plan to proceed and prohibit other parts.

The main component that the European Union stated it would not permit was nationwide adult-use cannabis sales to anyone of legal age. The blocking of that robust provision seemed to send many newer industry members into a bit of a spiral. The fact of the matter is that cannabis reform rarely, if ever, follows a linear path. It is full of twists and turns, and Germany is the latest example of that.

With those twists and turns comes opportunity, as not everyone is able to navigate the shifting landscape. People who are able to navigate the shifting landscape, that can identify trends, and maximize windows of opportunity, will reap significant rewards.

What legalization will ultimately look like in Germany once it is finally implemented is something that we will have to wait and see, however, the basic provisions are already known – personal cultivation, possession, and consumption will be legal and noncommercial clubs will be permitted.

Eventually, regional adult-use commerce pilot programs will launch as well. All of that creates opportunities for entrepreneurs, investors, and industry service providers if they know what to anticipate and where to focus on developing innovative ideas.

The best way to learn what is next for the emerging cannabis industry, both in Germany and beyond, is to hear from true international cannabis experts that spend every day on the frontlines of cannabis reform and industry. Fortunately, the upcoming International Cannabis Business Conference in Berlin, Germany later this month provides that exact opportunity.

Following yet another successful cannabis super-event in Barcelona, the International Cannabis Business Conference is once again bringing its flagship B2B event and tradeshow back to Berlin, Germany on June 29th-30th, 2023. In addition to the B2B event, which is the largest of its type in Europe, the International Cannabis Business Conference will also hold a Global Investment Forum in Berlin on June 27th.

Both events will feature leading cannabis industry experts, and the B2B event has a panel specifically dedicated to discussing what is next for the international cannabis industry now that the curtain dropped in Germany. The panel will feature:

Over 5,000 cannabis leaders from over 80 countries will be represented at the International Cannabis Business Conference in Berlin and that includes representatives from every sector of the industry as well as leading international cannabis policymakers and industry service providers.

Attend the International Cannabis Business Conference in Berlin to network with investors, entrepreneurs, industry regulators, and international policymakers and take your industry pursuits to the next level. Secure your tickets now before the event sells out!

Hemp Leaves No Longer A Novel Food Under EU Law

Cannabinoid-based products are increasing in popularity across the globe, and particularly so in Europe. ‘Cannabis light’ products are widely available in Europe, although they are not always completely legal.

Part of the problem is the patchwork of laws, rules, and regulations in Europe, with individual countries often having their own set of policies, with the European Union having sometimes conflicting policies. What is legal in one country may not be legal in another country, and all of it may be illegal in the eyes of the European Union depending on the situation.

To further complicate things, hemp and cannabis are treated differently by the governments of Europe (and elsewhere on earth), even though they are ultimately the same plant. If the THC content of a plant is under a threshold, typically .3-1%, then it is hemp. If it is above the threshold, then it is cannabis according to various governments.

It may seem like a big game of semantics to some, however, when it comes to public policy in Europe and the emerging industries that are governed by such policies, words matter. Thankfully, there is now reportedly clarification for hemp leaves at the European Union level, with the EU recently indicating that hemp leaves are no longer considered to be a ‘Novel Food.’ Per Cannabis Health News:

Hemp leaves, when separate from the flower, are now no longer classed as a Novel Food under EU law, permitting the sale of hemp-infused tea and tea-like products in member states.

An agreement to modify the Novel Food Catalogue was reached by EU members as part of a European Commission (EC) working group on Friday 2 June.

It’s now over four years since the EC made the controversial decision to classify all parts of the plants as Novel, meaning companies would need to apply for Novel Food status in order to legally sell cannabinoid-based products containing less than 0.3% THC in the EU.

The recent decision is obviously significant for people that sell cannabis teas and other products derived from hemp leaves. However, the decision clearly does not go far enough, and anything that is not derived from hemp leaves still faces a considerable amount of bureaucratic hurdles.

Europe’s emerging cannabis industry is increasing in size despite the playing field being far from level for cannabis companies compared to companies in many other major industries. Hopefully the governments of Europe, and the European Union itself, moves faster to modernize the continent’s cannabis policies.

Medical Cannabis Pilot Project Proposed In Iceland

The concept of cannabis commerce pilot projects is not a new thing and is seemingly growing in popularity among policymakers and regulators in Europe. The latest example of that can be found in Iceland, where a proposal was recently submitted to launch a medical cannabis-focused pilot project.

For those that may be unfamiliar with cannabis commerce pilot projects, medical and adult-use cannabis commerce projects allow jurisdictions to permit limited, legal cannabis commerce. The theory behind the concept is that it affords policymakers and regulators the opportunity to see how commerce works on a limited scale to be better suited to craft national policies.

Denmark currently has a medical-focused pilot program, and adult-use pilot programs are popping up in Switzerland. According to the current legalization plan in Germany, pilot programs will be part of the second phase of legalization once the details are figured out.

Iceland’s pilot project is somewhat different than what is going on in Switzerland, and eventually Germany, beyond just Iceland’s proposal being for medical versus adult use. One could easily argue that the proposal in Iceland is essentially an expansion of the nation’s medical cannabis program, albeit in a limited-duration fashion. Per Cannabis Health News:

Following a debate in Alþingi [Icelandic parliament] last week, officials have proposed a four-year pilot project to permit the use of medical cannabis, as well as the cultivation, production and distribution of cannabis-based products for medicinal use.

If approved, the Ministry of Health will work with the Minister of Culture and Trade to establish a working group to prepare a bill allowing companies to apply for licences to produce and distribute cannabis medicines.

The bill would need to be presented by the ministry by 31st December with the four-year pilot programme expected to begin on 1 January, 2024.

Currently, only the pharmaceutical product Sativex is available to suffering patients in Iceland, and even then, only in limited circumstances. Just as is the case everywhere around the globe, suffering patients in Iceland deserve to have safe, legal access to their medicine in whatever form helps them the best.

Only time will tell if the proposal in Iceland makes it to the finish line this year, and even if it does, whether or not 2024 will end up being the actual launch year. Pilot projects are notorious for experiencing delayed implementations. Hopefully that doesn’t prove to be the case in Iceland.